Cathay Biotechnology is a Biotech company dedicated to the production of innovative products through biochemical processes. Cathay Biotech was founded in 1997. The business model is to be a biotech business promoter, assisting with technology, engineering, sales and management.

    Since 1998, Cathay achieved significant success with the license of 6 biotechnologies, incubated by Cathay, to major Western companies.

    In 1999, Cathay extended its business model by taking equity shares in two Chinese biotech companies and assisted with management and technology issues. Both companies quickly achieved success, with the assistance of Cathay. One increased sales by 4 times and doubled production and the other improved plant economics. The investments generated a one-year return of over 50% for Cathay.

    In 2000, with the successful sale of a minority share in Cathay through a private placement, the company capital increased to USD 53,000,000. Cathay's expanded laboratory and office were opened in Shanghai Zhangjiang Hitech Park. After years of equity accumulation and team development, Cathay extended its business incubator model to the development of Cathay's own value-added, integrated multi-product biochemical and pharmaceutical facility in Jining, Shandong, China. In 2001, the pilot plant was put into production and the company began the investment of USD 140,000,000 to construct an integrated bioprocess facility for fermentation and biochemical process, supported by our own steam and electricity cogeneration. In early 2003 Cathay began production of dibasic acids at its fermentation facility located on 35 hectares in Jining, Shandong. All dibasic acids are currently available from two production lines. Cathay's 30 MW cogeneration facility supplys Cathay's facility and selling electricity to the China electric grid.

    Our R&D center, with a total capital of USD 23,500,000 has drawn great attention of Chinese government. In 2002, the central government of China has granted Cathay four national key biotech projects. Cathay already holds the exclusive, license on 25 technologies developed in China's national research laboratories. These technologies will be incubated in Cathay's expanded research and engineering facility. Further investments in established biochemical facilities are also planned.